Best-in-class
anticancer
drug
HLB研发的Rivocerenib追求Best-in-class
Rivoceranib为针对癌症优秀的靶向药物
Rivoceranib为针对癌症优秀的靶向药物
Leader of Global
Pharma
HLB navigates the way to the future by developing
First-in-class drugs with continuous innovation and challenges.
First-in-class drugs with continuous innovation and challenges.
IR Letter
-
About the Progress of the Global Ri...
∙ On February 26, HLB signed a binding term sheet with Adenchen Laboratories, the original developer of Rivoceranib, t... -
Apealea completes Pre-NDA meeting
On April 30th, Oasmia pharmaceutical AB (Oasmia) held FDA's ovarian cancer pre-NDA meeting for Apealea, which Elevar Th...
Press Release
-
HLB on a quest for next-generation...
SouthKoreanpharmaceuticalHLBCo.ispoisedtoventureintonewtherapeuticareas,includingchimericantigenreceptorTcell,orCAR-Tcel... -
HLB "Published in the 'Lancet' resu...
HLB announced on the 25th that the results of the first phase 3 global clinical trial of liver cancer using riboceranib,...